1 completed, 1 withdrawn. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow IPI-145: new trials by email Literature Review of IPI-145 trials Research Report on IPI-145
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) Duvelisib, Placebo, Rituximab - Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 3 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 IPI-145, Ofatumumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Completed | SecuraBio | 99 | 2013-12-01 | 2023-09-21 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1)
SecuraBio (2)
United States (2) · Australia (1) · Austria (1) · Belgium (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · New Zealand (1) · Spain (1) · United Kingdom (1)